Data Management Featured Articles

61. Can Sharing Clinical Notes Increase Patient Engagement And Retention? 2/25/2016

    If patients are more engaged with a study, and take more of an ownership role in their health and data, it’s believed they will become more attached to the study and the treatment. Some pharma companies are even looking into the possibility of patients being able to review and delete their own data. But what about notes that are recorded by a physician during a patient’s visit to a clinic? Should that information also be shared with patients?

62. ClinicalTrials.gov: Progress Made, But One-Third Of Results Still Missing 2/24/2016

    <p>ClinicalTrials.gov was created to inform the public of the results of clinical trials. Since the database went live in 2008, it has accumulated data on 200,000 trials in more than 170 countries. Compliance with established requirements is improving, but according to NIH data recently shared by Sen. Charles Grassley of Iowa, more than a third of applicable study results are still missing.</p>

63. Report: Pharma Is Most Resistant To Mobile Technology Use In Clinical Trials 2/17/2016

    There are several technologies that promise to improve the ease and efficiency of conducting clinical trials in the future. The one that seems to hold the most potential for also easing the burden on patients, and helping sponsors with patient recruitment and retention, is mobile health technologies. But is the adoption rate of mHealth in clinical trials increasing?

64. Clinical Outsourcing Market To See Continued Growth Through 2020 2/11/2016

    A recent report from ISR, titled 2016 CRO Market Size Projections 2015-2020, paints an exciting and eventful future for the clinical trials market. This market has certainly been one of the best performing of late. In 2015, while the DJIA was down around 10 percent, clinical companies like PRA Health (up 78 percent), INC Research (up 64 percent) ICON (up 19 percent), Quintiles (up 6 percent), and PAREXEL (up 2 percent), all had great years.

65. In Pharma Mobile Technology Makes Gains, Patient Enrollment Remains A Struggle 2/4/2016

    A new report has been released by Insight Pharma Reports with some eye-opening results sure to get the attention of clinical executives. The Patient Enrollment & Recruitment Market Study performed a survey of 100 clinical trial professional staff members regarding their experiences with patient enrollment and recruitment.

66. Using The Cost Of Adverse Events To Determine Drug Safety 2/3/2016

    There are limitations to the drug approval system we currently have in place that is based on clinical trials. Data disclosures are often deemed inadequate, regulatory review and approval can be a lengthy process, and many would argue there is a bias in the industry and academia against publishing negative results.

67. Patient-Reported Outcomes: Engaging Patients As Partners For Better Pharmacovigilance Practices 1/29/2016

    Today, there is greater awareness surrounding the benefit and risk of pharmaceutical products, amongst health care professionals (HCPs) and consumers alike. Safety and efficacy data from clinical trials are no longer sufficient and there is a demand for more evidence including effectiveness of treatments as well as comparative effectiveness, relative to other therapies.

68. Using Real-World Data For Clinical Research: Challenges And Opportunities 1/21/2016

    Across the country, there is growing awareness of challenges facing the clinical research enterprise. Among these challenges are the expense and logistical complexities of performing clinical trials, much of which is created by the need for elaborate, stand-alone data collection systems that are distinct from the systems used for normal clinical care.

69. MDR-TB Study Requires A New Approach To Trials 1/19/2016

    Otsuka Pharmaceutical has been an industry leader in TB drug development for over 30 years. The company is currently focused on MDR (multidrug-resistant)-TB, which refers to a form of the disease that is resistant to at least the two main first-line drugs available on the market.

    In a recent clinical trial, many of the sites lacked proper personnel, training, and equipment. Learn how the company overcame these challenges to make the trial a success.  

70. Mobile Devices In Clinical Trials: Tested, Effective, Proven! 1/11/2016

    Patient recruitment and retention remains a challenge for most pharma companies. New mobile tools bring the promise of a better patient experience, which would serve to alleviate both problems. And yet the conservative nature of pharma, coupled with regulatory concerns, seem to be keeping these solutions from gaining adoption. It’s no surprise that some technology companies are attempting to prove the effectiveness of these mobile tools themselves.